| Rare mutations in KRAS, NRAS, and BRAF oncogenes have been found in patients with melanoma and colorectal neoplasms. | skin,colorectal,neoplasm, |
| Analysis of the rasH oncogene and its p21 product in chemically induced skin tumors and tumor-derived cell lines. | skin, |
| Our finding of frequent KRAS mutation in urachal adenocarcinoma suggests its potential role in the oncogenesis of this neoplasm | neoplasm, |
| this study shows that intracellular high mobility group box 1 (HMGB1) remarkably suppresses oncogenic K-Ras-driven pancreatic tumorigenesis by inhibiting chromosome instability-mediated pro-inflammatory nucleosome release. | pancreatic, |
| Chromosomal and c-K-ras oncogene alterations induced by a chemical carcinogen and phorbol ester in skin fibroblasts of individuals with familial polyposis coli. | skin, |
| CDKN2B expression in HPDE6-C7 human pancreatic ductal cells is induced by oncogenic KRAS via TGF-beta signaling. | pancreatic, |
| This study shows that STK38L is co-amplified with oncogenic KRAS in pancreatic cancer cell lines, where it regulates LATS2 gene expression. | pancreatic, |
| RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in human cancer. With a near 100% KRAS mutation frequency, pancreatic ductal adenocarcinoma (PDAC) is considered the most RAS-addicted of all cancers. [review] | pancreatic, |
| Our data provide evidence that blocking TfR could significantly inhibit lung adenocarcinoma (LAC) proliferation by targeting the oncogene KRAS; therefore, TfR may be a therapeutic target for LAC. In addition, our results suggest a new method for blocking the signal from the oncogene KRAS by targeting TfR in LAC. | lung, |
| Mutations in both the p53 tumor suppressor gene and K-ras oncogene are highly frequent in lung tumors from nonsmoking women in China. The predominance of G-->T transversions in both genes and the occurrence of p53 mutations within a specific GC rich region or at specific hotspot codons on the non-transcribed strand are consistent with exposure to smoky coal emissions. | lung, |
| characteristics of the expression of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS) in non-small cell lung cancer | lymphoma,sarcoma,lung, |
| Colon carcinoma K-ras 2 oncogene of a familial polyposis coli patient. | colorectal, |
| Our study demonstrates that [(89)Zr]Zr-Tf is a valuable tool to noninvasively assess oncogene status and target engagement of small-molecule inhibitors downstream of oncogenic KRAS, allowing a quantitative assessment of drug delivery. | liver, |
| Immunocytochemical demonstration and significance of p21 ras family oncogene product in benign and malignant breast disease. | breast, |
| In mice that express oncogenic Kras in pancreatic cells, heterozygous disruption of Atg5 and reduced protein levels promotes tumor development, whereas homozygous disruption of Atg5 blocks tumorigenesis. | pancreatic, |
| Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin. | colorectal, |
| We observed that the designed ss-miR-216b mimics engaged AGO2 to promote the silencing of KRAS. We also tested a new delivery strategy based on the use of palmityl-oleyl-phosphatidylcholine (POPC) liposomes functionalized with ss-miR-216b conjugated with two palmityl chains and a lipid-modified cell penetrating peptide . These versatile nanoparticles suppressed oncogenic KRAS in pancreatic ductal adenocarcinoma cells | pancreatic,liver, |
| C/EBPB deletion in oncogenic Ras skin tumors is a synthetic lethal event. | skin, |
| Immunohistochemical detection of ras oncogene p21 product in liver cirrhosis and hepatocellular carcinoma. | liver, |
| Activated c-Ha-ras oncogene with a guanine to thymine transversion at the twelfth codon in a human stomach cancer cell line. | gastric, |